- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Gilead Sciences Inc.
Headquarters: Foster City, CA, United States
Website: http://www.gilead.com
Year Founded: 1987
Status: Public
Industry Sector: HealthTechnology
CEO: Daniel P. O'Day, MBA
Number Of Employees: 17,600
Enterprise Value: $131,594,350,000
PE Ratio: 20.64
Exchange/Ticker 1: NASDAQ:GILD
Exchange/Ticker 2: N/A
Latest Market Cap: $122,369,204,224
BioCentury | May 5, 2025
Deals
Amicus/Dimerix kidney partnership closely follows Regulus takeout: Deals Report
Plus: Creyon/Lilly, Concentra/Kronos, Novavax/Takeda and more
BioCentury | Apr 30, 2025
Management Tracks
Nocion, Engine among biotechs filling CMO, CSO posts
Hervolution, Contineum, Aclaris, Heron, Montai also bolster C-suite
BioCentury | Apr 22, 2025
Product Development
ADC successes in early-line breast cancer via combinations
Also in BioCentury’s Clinical Report: Lilly records an oral GLP-1 win, and new targeted radiotherapy data from Telix
BioCentury | Apr 21, 2025
Management Tracks
As Galapagos picks Gosebruch to lead spinout, Stoffels announces planned retirement
Plus: Roivant takes greater oversight role at Immunovant, installs new CEO; and more
BioCentury | Apr 11, 2025
Finance
Incubated at Third Rock, Merida moves Fc therapies toward clinic with $121M: Finance Report
Plus: Caris, Raythera, Immunitybio among those raising cash
BioCentury | Apr 5, 2025
Discovery & Translation
Science Spotlight: A FOXP3 regulator to enhance induced Tregs
BioCentury’s roundup of translational innovations also includes insights into high-fat diet disruption of feeding motivation; ER-targeted antigens; and more
BioCentury | Mar 27, 2025
Management Tracks
Thomas Butler steps down as Biomea CEO
Plus: Shane Olwill named chief development officer of Asgard, and updates from Tevogen and Verrica
BioCentury | Mar 20, 2025
Data Byte
FDA’s new and supplemental approvals in February
Springworks gets priority review voucher for Gomekli, first NovoLog biosimilar reaches market, and more
BioCentury | Mar 12, 2025
Deals
Chasing amylin: Must-have obesity target key to Roche-Zealand deal
Swiss pharma pays $1.7B upfront for Zealand’s petrelintide, adding obesity’s hottest target
Items per page:
1 - 10 of 3630